SA
MRNA icon

Syntax Advisors’s Moderna MRNA Stock Holding History

Syntax Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$223K Buy
2,155
+287
+15% +$32K 0.2% 151
2023
Q2 		$227K Buy
1,868
+135
+8% +$18K 0.18% 168
2023
Q1 		$266K Buy
1,733
+382
+28% +$63K 0.2% 112
2022
Q4 		$243K Sell
1,351
-460
-25% -$75.2K 0.2% 139
2022
Q3 		$214K Sell
1,811
-78
-4% -$11.8K 0.18% 168
2022
Q2 		$270K Buy
1,889
+227
+14% +$32.4K 0.23% 94
2022
Q1 		$286K Buy
1,662
+648
+64% +$109K 0.24% 94
2021
Q4 		$258K Buy
+1,014
New +$296K 0.19% 164

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Syntax Advisors's MRNA Position: Q3 2023 in Review

Syntax Advisors increased its Moderna (MRNA) stake by 15% in Q3 2023, buying an estimated $32K and bringing the position to 2,155 shares worth $223K. The position accounts for 0.2% of the portfolio, ranked #151.

Syntax Advisors first reported a position in MRNA in Q4 2021 and has held it in 8 quarters since. The position peaked at $286K in Q1 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Syntax Advisors held 2,155 shares of Moderna worth $223K as of Q3 2023.
  • Syntax Advisors bought 287 Moderna shares in Q3 2023, an estimated $32K.
  • Moderna made up 0.2% of Syntax Advisors's portfolio in Q3 2023, its #151 holding.
  • Syntax Advisors first reported a position in Moderna in Q4 2021 and has held it in 8 quarters since.
  • Syntax Advisors's Moderna position peaked at $286K in Q1 2022.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Syntax Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.